EP2389176A4 - Nouvelle thérapie pour maladie métabolique - Google Patents

Nouvelle thérapie pour maladie métabolique

Info

Publication number
EP2389176A4
EP2389176A4 EP10733152A EP10733152A EP2389176A4 EP 2389176 A4 EP2389176 A4 EP 2389176A4 EP 10733152 A EP10733152 A EP 10733152A EP 10733152 A EP10733152 A EP 10733152A EP 2389176 A4 EP2389176 A4 EP 2389176A4
Authority
EP
European Patent Office
Prior art keywords
metabolic disease
disease therapy
novel metabolic
novel
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10733152A
Other languages
German (de)
English (en)
Other versions
EP2389176A1 (fr
Inventor
Mark Gorrell
Sunmi Song
Xin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
University of Sydney
Original Assignee
Centenary Institute of Cancer Medicine and Cell Biology
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009900275A external-priority patent/AU2009900275A0/en
Application filed by Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney filed Critical Centenary Institute of Cancer Medicine and Cell Biology
Publication of EP2389176A1 publication Critical patent/EP2389176A1/fr
Publication of EP2389176A4 publication Critical patent/EP2389176A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
EP10733152A 2009-01-23 2010-01-22 Nouvelle thérapie pour maladie métabolique Withdrawn EP2389176A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2009900275A AU2009900275A0 (en) 2009-01-23 Novel metabolic disease therapy
PCT/AU2010/000066 WO2010083570A1 (fr) 2009-01-23 2010-01-22 Nouvelle thérapie pour maladie métabolique

Publications (2)

Publication Number Publication Date
EP2389176A1 EP2389176A1 (fr) 2011-11-30
EP2389176A4 true EP2389176A4 (fr) 2012-08-01

Family

ID=42355441

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10733152A Withdrawn EP2389176A4 (fr) 2009-01-23 2010-01-22 Nouvelle thérapie pour maladie métabolique

Country Status (3)

Country Link
US (1) US20120053222A1 (fr)
EP (1) EP2389176A4 (fr)
WO (1) WO2010083570A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011295030B2 (en) * 2010-08-27 2016-01-28 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
WO2013107820A1 (fr) 2012-01-17 2013-07-25 Universiteit Antwerpen Nouveaux inhibiteurs de fap
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
EP2730571A1 (fr) * 2012-11-12 2014-05-14 Universitat De Barcelona Dérivés de 1- [1- (benzoyl) -pyrrolidine-2-carbonyl] -pyrrolidine-2-carbonitrile
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
EP3050023B1 (fr) 2014-10-27 2021-08-25 Aseko, Inc. Gestion sous-cutanée de patient externe
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CA2993275C (fr) 2015-08-20 2022-06-21 Aseko, Inc. Conseiller de therapie pour la gestion du diabete
WO2018111989A1 (fr) 2016-12-14 2018-06-21 Purdue Research Foundation Imagerie et thérapie ciblées par une protéine d'activation des fibroblastes (fap)
CN110167583A (zh) 2016-12-15 2019-08-23 泰伦基国际有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
WO2018108161A1 (fr) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 Méthode et médicament pour la prévention et le traitement de l'obésité
TWI746581B (zh) * 2016-12-15 2021-11-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
WO2018129497A1 (fr) 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Procédés prédictifs et diagnostiques pour le cancer de la prostate
IL275333B2 (en) 2017-12-15 2023-09-01 Praxis Biotech LLC Inhibitors of fibroblast activation protein
CN113811529A (zh) 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
US20060264401A1 (en) * 2003-11-12 2006-11-23 Campbell David A Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1784645A2 (fr) * 2004-07-29 2007-05-16 Bayer HealthCare AG Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap
WO2006125227A2 (fr) * 2005-05-19 2006-11-23 Genentech, Inc. Composes inhibiteurs de proteines d'activation de fibroblastes et procedes
EP1760076A1 (fr) * 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
US20100105753A1 (en) * 2007-03-20 2010-04-29 Trustees Of Tufts College Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264401A1 (en) * 2003-11-12 2006-11-23 Campbell David A Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUGUSTYNS KOEN ET AL: "Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 15, no. 10, 1 January 2005 (2005-01-01), pages 1387 - 1407, XP002453370, ISSN: 1354-3776, DOI: 10.1517/13543776.15.10.1387 *
PIETER VAN DER VEKEN ET AL: "Irreversible Inhibition of Dipeptidyl Peptidase 8 by Dipeptide-Derived Diaryl Phosphonates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 23, 1 November 2007 (2007-11-01), pages 5568 - 5570, XP055077384, ISSN: 0022-2623, DOI: 10.1021/jm701005a *
See also references of WO2010083570A1 *
THOMAS LEO ET AL: "(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quina zolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 325, no. 1, 1 April 2008 (2008-04-01), pages 175 - 182, XP009105508, ISSN: 0022-3565, DOI: 10.1124/JPET.107.135723 *
VAN DER VEKEN P ET AL: "Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: Identification of dipeptide derived leads", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, vol. 18, no. 14, 15 July 2008 (2008-07-15), pages 4154 - 4158, XP022852919, ISSN: 0960-894X, [retrieved on 20080524], DOI: 10.1016/J.BMCL.2008.05.080 *

Also Published As

Publication number Publication date
WO2010083570A1 (fr) 2010-07-29
US20120053222A1 (en) 2012-03-01
EP2389176A1 (fr) 2011-11-30

Similar Documents

Publication Publication Date Title
EP2389176A4 (fr) Nouvelle thérapie pour maladie métabolique
GB0908957D0 (en) Therapeutic agents
EP2427183A4 (fr) Composés thérapeutiques
EP2424529A4 (fr) Nouveaux traitements thérapeutiques utilisant la centhaquine
EP2496704A4 (fr) Composés thérapeutiques
EP2490704A4 (fr) Composition thérapeutique
EP2456309A4 (fr) Composés thérapeutiques
GB0906026D0 (en) Therapeutic compounds
GB0910493D0 (en) Therapeutic agents
AU2009900275A0 (en) Novel metabolic disease therapy
GB0904261D0 (en) New therapeutic use
GB0917199D0 (en) Metabolic disorders
GB0922098D0 (en) Therapeutic use
GB0919114D0 (en) Therapeutic intervention
GB0900712D0 (en) Therapeutic compounds
GB0916308D0 (en) Therapeutic compounds
GB0911266D0 (en) Therapeutic compounds
GB0916608D0 (en) Therapeutic compounds
GB0903321D0 (en) Therapy
GB0903319D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0921244D0 (en) Therapy
GB0801410D0 (en) Therapeutic intervention
GB0903949D0 (en) Therapeutic agents
GB0902450D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WANG, XIN

Inventor name: SONG, SUNMI

Inventor name: GORRELL, MARK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120702

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 211/60 20060101ALI20120626BHEP

Ipc: A61K 31/275 20060101AFI20120626BHEP

Ipc: A61P 3/04 20060101ALI20120626BHEP

Ipc: C07F 5/02 20060101ALI20120626BHEP

Ipc: A61K 31/397 20060101ALI20120626BHEP

Ipc: C07D 205/02 20060101ALI20120626BHEP

Ipc: A61K 31/435 20060101ALI20120626BHEP

Ipc: C07D 207/16 20060101ALI20120626BHEP

Ipc: A61P 3/06 20060101ALI20120626BHEP

Ipc: A61P 3/10 20060101ALI20120626BHEP

Ipc: A61P 3/08 20060101ALI20120626BHEP

Ipc: A61K 31/426 20060101ALI20120626BHEP

Ipc: C07D 277/06 20060101ALI20120626BHEP

Ipc: A61K 31/401 20060101ALI20120626BHEP

Ipc: A61K 31/69 20060101ALI20120626BHEP

Ipc: C07F 9/02 20060101ALI20120626BHEP

17Q First examination report despatched

Effective date: 20130909

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140320